DNAL1 and autoimmune hepatitis: Type 2 AIH (about 5–10% of all AIH patients) is typically defined by anti-liver–kidney microsomal type 1 antibodies (anti-LKM-1) or, in rare cases, by anti-LKM-3 and/or anti-liver cytosol type 1 antibodies (anti-LC1) (12–14).